Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | HRH1 | P35367 | 1/20 | 0.66 |
| ▸ | HTR2B | P41595 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917362 | 0.92 | TACR1 (0.74) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6554762 | 0.90 | TACR1 (0.77) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4916022 | 0.86 | TACR1 (0.74) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4915629 | 0.84 | TACR1 (0.72) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4916174 | 0.84 | TACR1 (0.80) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6696862 | 0.84 | TACR1 (0.74) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6555202 | 0.84 | TACR1 (0.74) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL31401574 | 0.84 | TACR1 (0.77) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL31401610 | 0.84 | TACR1 (0.77) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL7822049 | 0.84 | TACR1 (0.80) | TACR1CYP2D6KCNH2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027892-B1 | Azithromycin combination for emesis control in dogs | PFIZER PROD INC (US) | 2005-08-17 | — | — | EP | claimed |
| CN-1525858-A | A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent for modulating cholinergic function | �Ʒ� | 2004-09-01 | — | — | CN | claimed |
| US-20040167200-A1 | Pharmaceutical composition and method of modulating cholinergic function in a mammal | PFIZER INC. | 2004-08-26 | — | — | US | claimed |
| EP-1404320-A2 | A PHARMACEUTICAL COMPOSITION COMPRISING A NICOTINIC RECEPTOR PARTIAL ANTAGONIST AND AN ANTIEMETIC AGENT FOR MODULATING CHOLINERGIC FUNCTION | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| US-20040063649-A1 | Azithromycin combination for emesis control in mammals | PFIZER INC | 2004-04-01 | — | — | US | claimed |
| WO-2003005998-A2 | A PHARMACEUTICAL COMPOSITION COMPRISING A NICOTINIC RECEPTOR PARTIAL ANTAGONIST AND AN ANTIEMETIC AGENT OF MODULATING CHOLINERGIC FUNCTION | PFIZER PRODUCTS INC. (US) | 2003-01-23 | — | — | WO | claimed |
| US-20030018049-A1 | Azithromycin combination for emesis control in mammals | GODEK DENNIS M (US) | 2003-01-23 | — | — | US | claimed |
| US-20030008892-A1 | Pharmaceutical composition and method of modulating cholinergic function in a mammal | PFIZER INC. | 2003-01-09 | — | — | US | claimed |
| US-20020016301-A1 | Azithromycin combination for emesis control in mammals | GODEK DENNIS M (US) | 2002-02-07 | — | — | US | claimed |
| EP-1027892-A2 | Azithromycin combination for emesis control in dogs | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| US-20080132538-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | PFIZER INC | 2008-06-05 | — | — | US | disclosed |
| US-20050256162-A1 | Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| EP-1027892-B1 | Azithromycin combination for emesis control in dogs | PFIZER PROD INC (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1562908-A1 | QUINOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-6894062-B1 | Quinoline derivatives | PFIZER INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-5773450-A | ANTIINFLAMMATORY AGENTS, CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1998-06-30 | — | — | US | disclosed |
| US-5744480-A | ANTIINFLAMMATORY AGENTS, NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0589924-B1 | FLUOROALKOXYBENZYLAMINO DERIVATIVES OF NITROGEN CONTAINING HETEROCYCLES | PFIZER (US) | 1996-09-04 | — | — | EP | disclosed |
| WO-1993000331-A1 | FLUOROALKOXYBENZYLAMINO DERIVATIVES OF NITROGEN CONTAINING HETEROCYCLES | PFIZER INC. (US) | 1993-01-07 | — | — | WO | disclosed |
| CN-1067655-A | FLUOROALKOXYBENZYLAMINO DERIVATIVES OF NITROGEN CONTAINING HETEROCYCLES | PFIZER (US) | 1993-01-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132538-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | NMUR2, NMUR1, NMBR | TACR1 41/4885CYP2D6 723/4885KCNH2 331/4885 |
| US-20050256162-A1 | Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | FPR3, CX3CR1, FPR1 | TACR1 564/4885CYP2D6 319/4885KCNH2 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.